Press release: Uppsala,
Fourth quarter, October-
- Net sales amounts to KSEK 0 (0)
- Earnings after financial items amounts to KSEK -15,661 (-8,604)
-
Earnings per share amounts to
SEK -0.02 (-0.06)
Financial year January-
- Net sales amounts to KSEK 0 (0)
- Earnings after financial items amounts to KSEK -44,157 (-31,756)
-
Earnings per share amounts to
SEK -0.08 (-0.26)
"Getting these positive study results feels like a validation of the quality of last year's development work. From the conclusion of preclinical studies in the spring, preparations for clinical trials, obtained regulatory approvals, to the launch in August. And all according to a timeline we publicly disclosed back in 2022", says
Significant events during the quarter
- Second part of the Phase 1 study, Multiple Ascending Dose, is initiated
- The first part of the phase 1 study, Single Ascending Dose, can be completed earlier than planned
- The warrants of series TO5 are subscribed to 85.4% which adds gross 16.5 MSEK
-
Dicot's preclinical program is presented at SMSNA,
North America 's largest sexual medicine conference
Significant events after the quarter
- Positive results from the first part of the phase 1 study are presented; showing a very good safety profile, no serious side effects, and a good exposure in the body
- Patent application is filed for a new manufacturing method of the starting material through cell culture
-
The preclinical research results are presented at the
European Society for Sexual Medicine
For further information, please contact:
Phone: +46 72 502 1010 Phone: +46 76 109 0000
E-mail: elin.trampe@dicot.se E-mail: bjorn.petersson@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at
Dicot is listed on
This information is information that
This disclosure contains information that
https://news.cision.com/dicot-ab--publ-/r/dicot-ab-year-end-report-2023,c3935311
https://mb.cision.com/Main/17172/3935311/2628474.pdf
https://mb.cision.com/Public/17172/3935311/96ae7cbb2c1dcd17.pdf
(c) 2024 Cision. All rights reserved., source